Equities

60 Degrees Pharmaceuticals Inc

SXTP:NAQ

60 Degrees Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.35
  • Today's Change-0.058 / -4.11%
  • Shares traded40.64k
  • 1 Year change-86.91%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 20:53 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year 60 Degrees Pharmaceuticals Inc had revenues fall -50.40% from 511.21k to 253.57k, though the company grew net income from a loss of 6.18m to a smaller loss of 3.77m.
Gross margin15.59%
Net profit margin-366.89%
Operating margin-2,113.98%
Return on assets-27.71%
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, 60 Degrees Pharmaceuticals Inc increased its cash reserves by 708.88%, or 1.88m. Cash Flow from Financing totalled 6.47m or 2,553.37% of revenues. In addition the company used 4.54m for operations while cash used for investing totalled 115.89k.
Cash flow per share-2.92
Price/Cash flow per share--
Book value per share2.98
Tangible book value per share2.74
More ▼

Balance sheet in USDView more

60 Degrees Pharmaceuticals Inc has a Debt to Total Capital ratio of 5.05%.
Current ratio3.09
Quick ratio2.74
Total debt/total equity0.0519
Total debt/total capital0.0505
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.